Author

H. M. Lee

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Organism:mouse· 2 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Azhdarnia· 1 shared A. K. Ghosh· 1 shared A. K. Kaushik· 1 shared A. K. Singh· 1 shared A. Sorokin· 1 shared A. T. Raman· 1 shared B. Faubert· 1 shared B. Ko· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Azhdarnia

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Synthetic glabridin derivatives mitigate steatohepatitis in a diet-induced biopsy-confirmed non-alcoholic steatosis hepatitis mouse model through paraoxonase-2

G.-C. Shin, H. M. Lee, N. Y. Kim, S.-K. Yoo, Y. S. Park, H. S. Park, D. Ryu, K. P. Kim, K.-H. Kim

This study shows synthetic glabridin derivatives reduce NASH symptoms in mice by activating autophagy and antioxidant defenses through targeting paraoxonase-2.

bioRxiv · Oct 1, 2021 · PreprintPharmacology & Toxicology

Chromatin State Dynamics Confers Specific Therapeutic Strategies in Enhancer Subtypes of Colorectal Cancer

E. Orouji, A. T. Raman, A. K. Singh, A. Sorokin, E. Arslan, A. K. Ghosh, J. Schulz, C. J. Terranova, M. Tang, M. Maitituoheti, S. C. Callahan, K. J. Tomczak, Z. Jiang, J. S. Davis, S. Ghosh, , K. Rai

This study identifies enhancer subtypes in colorectal cancer through epigenomic analysis and proposes targeted therapeutic strategies based on these subtypes.

bioRxiv · Sep 4, 2020Cancer Biology

The hexosamine biosynthesis pathway is a targetable liability in lung cancers with concurrent KRAS and LKB1 mutations.

J. Kim, F. Cai, B. Ko, C. Yang, H. M. Lee, N. Muhammad, K. Li, M. Haloul, W. Gu, B. Faubert, A. K. Kaushik, L. Cai, S. Kasiri, U. Marriam, K. Nham, , R. J. DeBerardinis

The paper identifies the hexosamine biosynthesis pathway as a metabolic vulnerability in KRAS/LKB1 mutant lung cancers and shows GFPT2 inhibition reduces tumor growth.

bioRxiv · Apr 13, 2020 · PreprintCancer Biology